All In Biotech

NDA 212904 · Aveo Pharms

Fotivda

Tivozanib Hydrochloride · Oral

Novel

CDER novel approval, Mar 10, 2021: To treat renal cell carcinoma

Last checked: Nov 19, 2026Latest source record: Jan 30, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Mar 10, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

40

5 Phase 3, 4 recruiting

FAERS reports

1,610

603 serious, 159 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 11, 2026.

FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA is a kinase inhibitor indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. ( 1 )

Mechanism: Tivozanib is a tyrosine kinase inhibitor. In vitro cellular kinase assays demonstrated that tivozanib inhibits phosphorylation of vascular endothelial growth factor receptor (VEGFR)-1, VEGFR-2 and VEGFR-3 and inhibits other kinases including c-kit and PDGFR β at clinically relevant concentrations. In tumor xenograft models in mice and rats, tivozanib inhibited angiogenesis, vascular permeability, and tumor growth of various tumor cell types including human renal cell carcinoma.

Therapeutic areas: Oncology · Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 10, 2021 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
2 products under this application
  • FOTIVDA · TIVOZANIB HYDROCHLORIDE EQ 1.34MG BASE · CAPSULE, ORAL · Prescription
  • FOTIVDA · TIVOZANIB HYDROCHLORIDE EQ 0.89MG BASE · CAPSULE, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Tivozanib" as an intervention, any sponsor and status, largest first.

All 40 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue316
  • diarrhoea196
  • blood pressure increased150
  • nausea142
  • disease progression139
  • decreased appetite135
  • dysphonia112
  • death106
  • asthenia93
  • off label use93
  • hypertension83
  • vomiting73

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20116
20122
201314
20142
20151
20172
20185
20199
20205
2021349
2022581
2023230
202475
2025209
2026120

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Fotivda (Tivozanib HCl)

2024 spending

$119M

Beneficiaries

993

4,132 claims

Per beneficiary

$119,739

$1,391.32 per unit

View as table
YearSpending
2020$0
2021$22,459,910
2022$72,738,998
2023$102,301,659
2024$118,900,829

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 40 on PubMed

Sponsor: Aveo Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.